相关实验视频

Updated: Jun 4, 2025

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics

Published on: October 2, 2014

在BRCA1,p53-缺乏的乳腺瘤细胞中,多西素的反应受到亨廷丁和BAP1的影响

Martín González-Fernández^1,2, Carmen Perry^1,2, Nora Merete Gerhards¹

¹Department of Infectious Diseases and Pathobiology, Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, 3012 Bern, Switzerland.

Proceedings of the National Academy of Sciences of the United States of America

|December 20, 2024

概括

亨廷丁 (HTT) 损失通过影响线性子,使BRCA1缺陷的乳腺癌细胞对多塞素敏感. BAP1的枯竭保护了这些细胞,为三阴性乳腺癌 (TNBC) 提供了新的治疗点.

科学领域:

在瘤学瘤学.
细胞生物学细胞生物学
遗传学遗传学是一种遗传学.

背景情况:

塔克森是诱导线性错误的化疗药物,对癌细胞死亡至关重要.
染色体不稳定性 (CIN) 是癌症的标志,如BRCA1缺陷三阴性乳腺癌 (TNBC).
了解BRCA1缺陷TNBC中多塞塔克塞尔的机制对于向治疗至关重要.

研究的目的:

调查BRCA1缺陷TNBC中多塞塔克塞尔诱导的细胞毒性机制.
在染色体不稳定 (CIN+) 细胞中识别调解多塞素反应的基因.
探索亨廷丁 (HTT) 和BRCA1相关蛋白-1 (BAP1) 在BRCA1缺乏的CIN+细胞中的作用.

主要方法:

在CIN+细胞中进行了功能性遗传查,以识别dcetaxel响应基因.
基因工程小鼠乳腺瘤细胞 (Brca1-/-;p53+/-) 用于模拟人类BRCA1缺陷TNBC.
分析了 HTT 损失和 BAP1 枯竭对线粒体动力学和中心体聚类的影响.

主要成果:

通过缩短线性杆杆和增加多极性,对对dosexel敏感的brca1缺乏的乳腺瘤细胞的丧失.
BAP1的枯竭保护了这些细胞免受螺丝轴的异常,恢复了螺丝轴的长度,并增强了中心细胞的聚类.
在dcetaxel响应的背景下,确定了HTT和BAP1之间的相互作用.

结论:

在BRCA1缺陷细胞中,HTT和BAP1在调节线粒旋多极性和中心体聚类方面发挥着至关重要的作用.
这些发现突出了HTT和BAP1对细胞对微管向剂的反应的影响.
针对HTT和BAP1与线粒体的相互作用,可能为BRCA1缺乏的TNBC提供新的治疗策略.

关键词:

这就是BRCA1的原因.在狩猎中寻找.染色体的不稳定性纳税人就是纳税人.三重阴性乳腺癌是什么

更多相关视频

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers

Published on: February 20, 2017

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

The Intrinsic Apoptotic Pathway

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...